161 related articles for article (PubMed ID: 21057378)
41. [Two resected cases of pulmonary metastasis from post operative colorectal cancer after preoperative chemotherapy with FOLFOX].
Koshiishi H; Park S; Matsuyama T; Goto H; Kakimoto Y; Sakamoto K; Nishida K; Okamura T; Minami T; Kato H; Maruyama M; Takahashi E; Koshiishi Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2201-3. PubMed ID: 20037370
[TBL] [Abstract][Full Text] [Related]
42. Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials.
Oweira H; Giryes A; Mannhart M; Decker M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):1069-1074. PubMed ID: 30099922
[TBL] [Abstract][Full Text] [Related]
43. [Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer].
Huang CX; Li ZY; Jiang YQ; Duan GL; Wang QQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Sep; 13(9):661-3. PubMed ID: 20878571
[TBL] [Abstract][Full Text] [Related]
44. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Lin L; Zhang Z; Zhang W; Wang L; Wang J
Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
[TBL] [Abstract][Full Text] [Related]
45. Nonspecific but significant.
Chen YG; Kao WY; Tsai SH
Am J Med; 2012 May; 125(5):461-4. PubMed ID: 22482844
[No Abstract] [Full Text] [Related]
46. Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX.
Sawayama H; Hayashi N; Honda S; Baba Y; Toyama E; Watanabe M; Takamori H; Beppu T; Baba H
Int J Clin Oncol; 2010 Feb; 15(1):70-6. PubMed ID: 20087616
[TBL] [Abstract][Full Text] [Related]
47. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
Delgado-Ureña M; Ortega FG; de Miguel-Pérez D; Rodriguez-Martínez A; García-Puche JL; Ilyine H; Lorente JA; Exposito-Hernandez J; Garrido-Navas MC; Delgado-Ramirez M; Serrano MJ
J Transl Med; 2018 Sep; 16(1):251. PubMed ID: 30189880
[TBL] [Abstract][Full Text] [Related]
48. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma.
Chang PM; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer Sci; 2009 Feb; 100(2):278-83. PubMed ID: 19068092
[TBL] [Abstract][Full Text] [Related]
49. Metastatic paediatric colorectal carcinoma.
Woods R; Larkin JO; Muldoon C; Kennedy MJ; Mehigan B; McCormick P
Ir Med J; 2012 Mar; 105(3):88-9. PubMed ID: 22558819
[TBL] [Abstract][Full Text] [Related]
50. Review article: benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer.
Mitry E; Rougier P
Aliment Pharmacol Ther; 2009 Jan; 29(2):161-71. PubMed ID: 18945257
[TBL] [Abstract][Full Text] [Related]
51. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
[TBL] [Abstract][Full Text] [Related]
52. Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer.
Ducreux M
Clin Adv Hematol Oncol; 2021 Dec; 19 Suppl 24(12):6-11. PubMed ID: 35289797
[No Abstract] [Full Text] [Related]
53. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
Tian S; Wang F; Lu S; Chen G
Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
[TBL] [Abstract][Full Text] [Related]
54. Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports.
El-Hout S; Lopez L; Schaeverbeke T; Richez C; Kostine M; Truchetet ME
Rheumatology (Oxford); 2021 Feb; 60(2):e47-e49. PubMed ID: 32875310
[No Abstract] [Full Text] [Related]
55. Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8.
Wu T; Wang Z; Liu Y; Mei Z; Wang G; Liang Z; Cui A; Hu X; Cui L; Yang Y; Liu CY
Clin Immunol; 2014 Oct; 154(2):116-26. PubMed ID: 25063444
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic
Hamad A; Singhi AD; Bahary N; McGrath K; Amarin R; Zeh HJ; Zureikat AH
J Natl Compr Canc Netw; 2017 Aug; 15(8):983-988. PubMed ID: 28784859
[TBL] [Abstract][Full Text] [Related]
57. Undiagnosed Case of Signet Ring Cell Colorectal Carcinoma: A Case Report and Review of the Literature.
Henry M; Delavari N; Webber J
Clin Colorectal Cancer; 2020 Sep; 19(3):e83-e86. PubMed ID: 32586730
[No Abstract] [Full Text] [Related]
58. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
[TBL] [Abstract][Full Text] [Related]
59. Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
Tenti S; Correale P; Conca R; Pastina P; Fioravanti A
J Chemother; 2012 Aug; 24(4):245-6. PubMed ID: 23040694
[No Abstract] [Full Text] [Related]
60. Irinotecan and mismatch repair deficiency.
Power DG; Feilchenfeldt J
Ann Oncol; 2010 Feb; 21(2):432-433. PubMed ID: 19940003
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
